FIELD: medicine.
SUBSTANCE: pharmaceutical composition is intended for cancer treatment. As active ingredient composition contains suberoylanilide-hydroxamic acid (SAHA) or its pharmaceutically acceptable salt or hydrate. Invention also relates to method of obtaining crystalline active ingredient SAHA.
EFFECT: definite profile of SAHA particles distribution according to their size, which in its turn results in improved profile of solubility in vitro and optimal SAHA bioavailability.
27 cl, 16 dwg, 22 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF FINAL DIFFERENTIATION INDUCTION | 2010 |
|
RU2530648C2 |
| CANCER THERAPY WITH USING HDAC INHIBITORS | 2004 |
|
RU2356547C2 |
| VINORELBINE MONOTARTRATE AND ITS PHARMACEUTICAL APPLICATION | 2016 |
|
RU2730521C2 |
| METHOD OF INDUCTION OF TERMINAL DIFFERENTIATION | 2003 |
|
RU2320331C2 |
| METHOD OF INDUCING TERMINAL DIFFERENTIATION | 2003 |
|
RU2394022C2 |
| SYSTEMS OF MEDICATION DELIVERY, INCLUDING SOLID SOLUTIONS OF WEAK-BASE MEDICATIONS | 2007 |
|
RU2434630C2 |
| FORMULATIONS OF NON-OPIOID AND LIMITED OPIOID ANALGESICS | 2007 |
|
RU2477995C2 |
| SOLID DOSAGE FORMS OF PALLBOCYCLOB | 2016 |
|
RU2686840C1 |
| METHOD OF PRODUCING PHENYLEPHRINE RESINATE PARTICLES, PHENYLEPHRINE RESINATE PARTICLES AND USING PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL COMPOSITIONS | 2015 |
|
RU2727204C2 |
| APPLICATION OF CALCITONIN FOR TREATING RHEUMATOID ARTHRITIS | 2006 |
|
RU2453330C2 |
